profile following atorvastatin treatment. Results: Atorvastatin treatment of PC3 cells for 24 h increased the expression of GFP-LC3-II by >25% and expression continued for >72 h, while apoptosis was not significantly induced within this time period. Four genes associated with the autophagy machinery were also significantly upregulated. Conclusions: In the presence of atorvastatin, autophagy may be unable to abrogate cell damage and may therefore contribute to cellular dysfunction, leading to autophagic/ type II programmed cell death. In response to atorvastatin treatment, the expression of genes involved in autophagic mediating pathways may have a role in tumor suppression. Objective: To evaluate whether the single nucleotide polymorphism (SNP), rs1805415 in the PARP1 gene impact alone or in combination on overall survival (OS) in patients with bladder cancer of Gansu province. Methods: The association between PARP1 genetic polymorphisms and clinicopathologic characteristics of 144 patients with BC was analyzed using QuantStudio™ 12K Flex Real-Time PCR System clamping. Results: The PARP1 genotype had a notable impact on OS. Kaplan-Meier analysis estimates a decreasing OS (P=0.020) between CC, CT and TT genotype patients, survival curves were calculated for overall according to the PARP1 genotypes and between C-allele and T-allele. However, patients with TT genotype had significantly shorter survival time compared with the (CT + CC) genotype patients. In multivariate analysis, revealed that pathological classification (HR 4.183, P=0.025), smoking status (HR 6.202, P=0.048) and recurrence (HR 32.529, P=0.003) were found to be a strong independent prognosticator with marked increased risk for poor OS in different genotype. Despite the close correlation between PARP1-SNP and survival in univariate analysis, there was no significant difference in the probabilities of overall survival between the genotypes (P=0.832) in this study cohort. Conclusions: Analysis of genotypes and clinical data for bladder cancer patients indicates that the PARP1 rs1805415 genotype may be a useful prognostic genetic marker for bladder cancer.

